MX378282B - Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma. - Google Patents

Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma.

Info

Publication number
MX378282B
MX378282B MX2018002759A MX2018002759A MX378282B MX 378282 B MX378282 B MX 378282B MX 2018002759 A MX2018002759 A MX 2018002759A MX 2018002759 A MX2018002759 A MX 2018002759A MX 378282 B MX378282 B MX 378282B
Authority
MX
Mexico
Prior art keywords
crystal
compound
formula
androgen receptor
receptor inhibitor
Prior art date
Application number
MX2018002759A
Other languages
English (en)
Other versions
MX2018002759A (es
Inventor
Changshan Guo
Guaili Wu
Liang Zhong
Yun Lu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018002759A publication Critical patent/MX2018002759A/es
Publication of MX378282B publication Critical patent/MX378282B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan una forma cristalina de un inhibidor del receptor androgénico, y un método de preparación de la misma. En términos particulares, se proporcionan un cristal tipo I de (S)-4-(3-(4-(2,3-dihidroxipropoxi)fenil)-4,4-dimetil-5-carbonil-2-tioimidazolin-1-il)-2-(trifluorometil)benzonitrilo (un compuesto de la fórmula (I)) y un método de preparación del mismo, en donde el método comprende: 1) se agrega cualquier forma cristalina o forma amorfa del compuesto como se muestra por la fórmula (I), a una cantidad adecuada de un solvente orgánico, se calienta y se disuelve hasta que esté transparente, seguido por enfriamiento y cristalización, en donde el solvente orgánico se selecciona a partir de cualquiera de ésteres, cetonas, nitrilos y éteres que tienen 5 o menos átomos de carbono, o un solvente mixto del mismo; y 2) el cristal se filtra, lava y seca. El cristal tipo I obtenido del compuesto de la fórmula (I) tiene una buena estabilidad química y estabilidad de su forma cristalina, y el solvente de cristalización utilizado tiene una baja toxicidad y poca formación de residuos, y se puede utilizar mejor en tratamientos clínicos.
MX2018002759A 2015-09-10 2016-08-23 Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma. MX378282B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510574141 2015-09-10
CN201610073458 2016-02-02
PCT/CN2016/096381 WO2017041622A1 (zh) 2015-09-10 2016-08-23 一种雄性激素受体抑制剂的结晶形式及其制备方法

Publications (2)

Publication Number Publication Date
MX2018002759A MX2018002759A (es) 2018-08-01
MX378282B true MX378282B (es) 2025-03-10

Family

ID=58240573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002759A MX378282B (es) 2015-09-10 2016-08-23 Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma.

Country Status (23)

Country Link
US (1) US10150739B2 (es)
EP (1) EP3348546B1 (es)
JP (1) JP6843116B2 (es)
KR (1) KR20180048939A (es)
CN (1) CN107001284B (es)
AU (1) AU2016318700B2 (es)
BR (1) BR112018003258A2 (es)
CA (1) CA2996674A1 (es)
CY (1) CY1123027T1 (es)
DK (1) DK3348546T3 (es)
ES (1) ES2794568T3 (es)
HR (1) HRP20200852T1 (es)
HU (1) HUE050459T2 (es)
LT (1) LT3348546T (es)
MX (1) MX378282B (es)
PL (1) PL3348546T3 (es)
PT (1) PT3348546T (es)
RS (1) RS60448B1 (es)
RU (1) RU2018109121A (es)
SI (1) SI3348546T1 (es)
SM (1) SMT202000258T1 (es)
TW (1) TWI708764B (es)
WO (1) WO2017041622A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3348546T3 (da) 2015-09-10 2020-07-06 Jiangsu Hengrui Medicine Co Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf
CN112174895B (zh) * 2017-12-13 2022-06-21 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的晶型及其制备方法
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
EP2416657A4 (en) * 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
SI2894151T1 (sl) * 2012-09-04 2021-01-29 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
KR20150053963A (ko) * 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
DK3348546T3 (da) 2015-09-10 2020-07-06 Jiangsu Hengrui Medicine Co Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf

Also Published As

Publication number Publication date
ES2794568T3 (es) 2020-11-18
JP2018526364A (ja) 2018-09-13
RS60448B1 (sr) 2020-07-31
RU2018109121A3 (es) 2019-12-04
WO2017041622A1 (zh) 2017-03-16
PL3348546T3 (pl) 2020-09-21
AU2016318700A1 (en) 2018-04-05
BR112018003258A2 (pt) 2018-09-25
CY1123027T1 (el) 2021-10-29
AU2016318700B2 (en) 2020-05-07
SMT202000258T1 (it) 2020-07-08
KR20180048939A (ko) 2018-05-10
PT3348546T (pt) 2020-05-29
HRP20200852T1 (hr) 2020-08-21
DK3348546T3 (da) 2020-07-06
CN107001284B (zh) 2019-11-22
CN107001284A (zh) 2017-08-01
HUE050459T2 (hu) 2020-12-28
SI3348546T1 (sl) 2020-09-30
CA2996674A1 (en) 2017-03-16
EP3348546A1 (en) 2018-07-18
US20180244628A1 (en) 2018-08-30
LT3348546T (lt) 2020-07-27
MX2018002759A (es) 2018-08-01
US10150739B2 (en) 2018-12-11
RU2018109121A (ru) 2019-10-10
JP6843116B2 (ja) 2021-03-17
EP3348546A4 (en) 2019-03-27
TWI708764B (zh) 2020-11-01
EP3348546B1 (en) 2020-04-29
TW201713628A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
HRP20210507T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku
JOP20250289A1 (ar) صور بلورية جديدة
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
RU2016144197A (ru) Фунгицидные производные n'-[2-метил-6[2-алкоксиэтокси]-3-пиридил]-n-алкилформамидина для применения в сельском хозяйстве
EA201270676A1 (ru) Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3- илтио)ацетата натрия и их применение
EA201291236A1 (ru) Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
CL2018000241A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido.
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EA201690094A1 (ru) Ингибиторы syk
EA201590023A1 (ru) Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
EA201590548A1 (ru) Кристаллические формы ингибитора фактора xia
PE20141191A1 (es) Compuestos como inhibidores de bace
WO2014147021A3 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
HRP20191431T1 (hr) Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida i njegovo pročišćavanje za uporabu kao aktivni farmaceutski pripravak
CY1123027T1 (el) Κρυσταλλικη μορφη αναστολεα υποδοχεα ανδρογονων και μεθοδος παρασκευης αυτου
MX2016008536A (es) Derivados de fluoro-naftilo.
PE20151748A1 (es) Inhibidores de bace1
EA201891023A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
MX2021011971A (es) Proceso para preparar cicloserinas sustituidas.
JP2016529315A5 (es)
RU2016107830A (ru) Производное замещенного пиразолилпиразола и его применение в качестве гербицида
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
PE20181002A1 (es) Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana